Posts by: Jose Marques Lopes, PhD

News

Treatment with Tyvyt (sintilimab injection) was found safe and eased the tumor burden or led to cancer disappearance in nearly 3 out of 10 patients with relapsed or refractory ... Read more

March 15, 2019

Phase 1/2 Trial of Tinostamustine to Treat Blood Cancers Opens 2nd Stage

News

The expansion stage of a Phase 1/2 trial testing tinostamustine in relapsed or refractory types of lymphoma and other blood cancers has enrolled a first patient. The study (NCT02576496) is ... Read more

March 7, 2019

$12.5M Grant to Help City of Hope Develop New Lymphoma Immunotherapies

News

The National Cancer Institute (NCI) has awarded a five-year $12.5 million grant to City of Hope that may help improve treatment by using a vaccine, develop an immunotherapy to ... Read more

March 1, 2019

FDA Grants Priority Review for Revlimid-Rituxan Combo for Some Lymphomas

News

The U.S. Food and Drug Administration (FDA) has granted priority review to Revlimid (lenalidomide) in combination with Rituxan (rituximab) for patients with previously treated follicular and marginal zone lymphoma. A ... Read more

February 27, 2019

FDA Grants Priority Review to Polatuzumab Vedotin Combo for Difficult-to-treat DLBCL

News

The U.S. Food and Drug Administration has granted priority review to Roche‘s polatuzumab vedotin in combination with Rituxan (rituximab) and the chemotherapy bendamustine for the treatment of patients with relapsed or ... Read more

February 26, 2019

Yescarta Approved in Canada for Adults with Relapsed or Refractory Large B-cell Lymphoma

News

Health Canada has approved Yescarta (axicabtagene ciloleucel) as a treatment for adults with diffuse large B-cell lymphoma (DLBCL) who have already received two or more lines of systemic therapy. ... Read more

February 21, 2019

First Patient Dosed in Trial of ADCT-402 for Advanced Non-Hodgkin’s Lymphoma

News

A Phase 1 trial testing the combination of ADCT-402 (loncastuximab tesirine) with Imfinzi (durvalumab) in multiple types of advanced non-Hodgkin’s lymphoma has dosed the first patient. The study (NCT03685344) is for ... Read more

February 14, 2019

FDA Update Shows 457 Cases of ALCL Linked to Breast Implants

News

The number of reported cases of anaplastic large cell lymphoma associated with breast implants (BIA-ALCL) has risen to 457, according to a 2018 update from the U.S. Food and Drug ... Read more

February 12, 2019

Experts Propose New Consensus Scale for CAR T-cell Therapy Toxicities

News

The American Society for Blood and Marrow Transplantation (ASBMT) proposed a new consensus scale for toxicities associated with CAR T-cell therapies to better categorize their severity in both the hospital ... Read more

February 8, 2019

U.K. Institute Recommends Kymriah for Adults with Aggressive DLBCL

News

The U.K.’s National Institute for Health and Care Excellence (NICE) has recommended that Kymriah (tisagenlecleucel) be offered to patients with difficult-to-treat diffuse large B-cell lymphoma (DLBCL) through the Cancer Drugs Fund. Specifically, this Novartis-developed ... Read more

Posts by: Jose Marques Lopes, PhD

Jose Marques Lopes, PhD

Tyvyt Effective, Safe in Previously Treated Patients with Hodgkin’s Lymphoma, Phase 2 Trial Shows

Phase 1/2 Trial of Tinostamustine to Treat Blood Cancers Opens 2nd Stage

$12.5M Grant to Help City of Hope Develop New Lymphoma Immunotherapies

FDA Grants Priority Review for Revlimid-Rituxan Combo for Some Lymphomas

FDA Grants Priority Review to Polatuzumab Vedotin Combo for Difficult-to-treat DLBCL

Yescarta Approved in Canada for Adults with Relapsed or Refractory Large B-cell Lymphoma

First Patient Dosed in Trial of ADCT-402 for Advanced Non-Hodgkin’s Lymphoma

FDA Update Shows 457 Cases of ALCL Linked to Breast Implants

Experts Propose New Consensus Scale for CAR T-cell Therapy Toxicities

U.K. Institute Recommends Kymriah for Adults with Aggressive DLBCL

Pin It on Pinterest